title: [Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?].
abstract: Different families of dopaminergic agents have allowed to increase the availability of dopamine within the central nervous system by different mechanisms of action. Each drug family has specific efficacious properties, as well as a different profile of adverse events. The knowledge in detail of these specificities is mandatory to avoid severe systemic or neuropsychiatric complications. Despite these limitations, the development of new drugs within the past 20 years has prolonged survival in Parkinson's disease, increasing the time with preserved daily day functionality compared with the levodopa era, when this drug was the only dopaminergic drug available. The correct combination of dopaminergic drugs with different mechanisms of action allows the management of Parkinson's disease motor symptoms within safety dose ranges, and up to day, this appears as the best algorithm to maintain functionality for longer periods of time.
authors.affiliation: Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Espana.
authors.forename: Javier
authors.initials: J
authors.lastname: Pagonabarraga
authors.forename: Jaume
authors.initials: J
authors.lastname: Kulisevsky
mesh_terms: D000547:Amantadine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002394:Catechol O-Methyltransferase; D065098:Catechol O-Methyltransferase Inhibitors; D002986:Clinical Trials as Topic; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018565:Food-Drug Interactions; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use; D001523:Mental Disorders / Q000139:chemically induced / Q000517:prevention & control; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D010300:Parkinson Disease / Q000188:drug therapy*; D020230:Serotonin Syndrome / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D018491:Dopamine Agonists; D004791:Enzyme Inhibitors; D007189:Indans; D007211:Indoles; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline; C046649:ropinirole; D007980:Levodopa; D000547:Amantadine; C588010:COMT protein, human; D002394:Catechol O-Methyltransferase